声明：因水平有限，错误不可避免，或有些信息非最及时，欢迎留言指出。本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及）;本文不构成任何投资建议。武田制药近日公布2025财年上半年（4月至9月）业绩报告，期内营收为2.2万亿日元（约合143亿美元），较去年同期下滑约4%。为扭转局面，武田一方面大刀阔斧地削减早期研发管线，精简布局；另一方面则战略性押注中国创新，本月与信达生物的一笔首付高达12亿美元...
Source Link声明：因水平有限，错误不可避免，或有些信息非最及时，欢迎留言指出。本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及）;本文不构成任何投资建议。武田制药近日公布2025财年上半年（4月至9月）业绩报告，期内营收为2.2万亿日元（约合143亿美元），较去年同期下滑约4%。为扭转局面，武田一方面大刀阔斧地削减早期研发管线，精简布局；另一方面则战略性押注中国创新，本月与信达生物的一笔首付高达12亿美元...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.